Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

RemeGen Completes Enrollment in Two Phase III Trials for Autoimmune Diseases

publication date: May 21, 2024

Yantai’s RemeGen (HK: 9995: SHA: 688331) announced that two China Phase III trials for Telitacicept (RC18) have completed enrollment, one for IgA nephropathy and the other for primary Sjögren's syndrome (pSS). Telitacicept is a proprietary novel fusion protein aimed at treating autoimmune diseases. It targets two cell-signaling molecules critical for B-lymphocyte development: B-lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL) that reduces B-cell mediated autoimmune responses implicated in several autoimmune diseases. Telitacicept was granted China approval for systemic lupus erythematosus in 2023. More details....

Stock Symbols: (HK: 9995: SHA: 688331)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital